Title : The Economics of Diabetes - DT2 12
link : The Economics of Diabetes - DT2 12
The Economics of Diabetes - DT2 12
Insulin, first discovered in 1921, revolutionized the treatment of type 1 diabetes Dr. Banting insulin license pharmaceutical companies without a patent because he believed that this drug save the life of DM1 should be made available to all people in need. So, why is it so difficult insulin afford today?
Only three pharmaceutical companies manufacture insulin in the United States - Eli Lilly, Sanofi and Novo Nordisk. In 2012, an estimated insulin alone costs the US health system $ 6 billion. How can you make a lot of money from an old product of the century? In 2013, according to firecepharma.com , the best selling drug was .... Lantus diabetes, a form of long-acting insulin. So, after all the investigations of the past 95 years, the biggest money Makin 'mama-shakin' drug was insulin? Yes sir. Globally, this drug only made $ 7,592 million. That's billion with a B Oh, but the news is better for large insulin. Outside the top ten, different insulins also ranked # 3, 4, 6,7,9, and 10 patent extensions Holy Batman! A total of seven of the ten best medications for diabetes are insulin - a drug nearly a century old. It's like your grandfather 95 years by beating LeBron James in basketball. 
Optimising the insulin molecule allows additional patents and cheaper generic drugs can be kept at bay. This clearly violates the original intent of Dr. Banting does not matter. There is no clear evidence that these newer insulins are more effective than the old rules. While there are some theoretical advantages, results in type 2 diabetes have only worsened even when these newer insulins became more widely prescribed. Hiking is another lucrative prices technique. From 2010 to 2015, the price of the new insulins rose from 168- 325%. Without generic competition, there is a clear collusion among companies to keep prices high. After all, shareholders must be kept happy and the CEO need a private jet.
At the time of the discovery of insulin, though still relatively rare, type 2 diabetes had few treatments available. Metformin, the most powerful of the biguanide class of drugs was discovered shortly after insulin and described in the scientific literature in 1922. In 1929, its reducing effect of sugar was observed in animal studies, but it was not until 1957 which it was first used in humans for the treatment of diabetes.
He entered the British National Formulary in 1958, and entered Canada in 1972. It was not approved by the FDA in the United States until 1994 due to concerns about lactic acidosis. Now is the most prescribed medication for diabetes in the world.
The sulfonylurea class of drugs was discovered in 1942 were introduced in 1956 in Germany. By 1984, SUs second generation were introduced more powerful in the United States. These drugs stimulate the pancreas to release more insulin, which reduces sugar levels. There were many side effects, including severe hypoglycemia, but proved to be effective in reducing blood sugar. For decades, these two drug classes were the only oral medication for the treatment of type 2 diabetes
Even while the number of blood pressure and cholesterol medications were exploiting the class of hypoglycemic drugs oral was mired in a slump. Simply, there was no money to be made for pharmaceutical companies. The number of patients were too small, and the benefits of these drugs were dubious. But things soon changed. 
In 1977, the Dietary Guidelines for Americans were introduced to an unsuspecting American public and dietary fat was Public Enemy # 1. guzzling later carbohydrates would unintended consequences and soon flourished epidemic of obesity. What follows like a sick puppy love was the epidemic of type 2 diabetes
In 1997, the American Diabetes Association lowered the blood sugar definition of type 2 diabetes, instantly rendering as much as 1.9 million more Americans as diabetics.
Prediabetes underwent a similar change in the definition label in 2003. This would be 25 million more Americans as pre-diabetic. With an increasing number, the business case for developing diabetes medications completely changed. While there is broad consensus that pre-diabetes is best treated with lifestyle changes, advocacy groups soon adopted the concept of drug therapy. The guidelines have been lowered so much that by 2012, the prevalence of diabetes in US adults was 14.3% and 38% prediabetes, totaling 52.3% of Americans are considered pre-diabetic or or diabetic. This was the new normal. It was more common to have pre-diabetes or diabetes of what was to have normal blood sugar. Diabetes is the new black.
In 1999, the economy was primed diabetes booming. In 1999, rosiglitazone and pioglitazone were approved by the FDA for the treatment of type 2 diabetes They have subsequently fallen into disuse because of concerns about lead to heart disease and bladder cancer. But it mattered little. The dam had burst. From 2004- 2013, no fewer than thirty new diabetes drugs were brought to market.
2015 sales of diabetes medicines had reached $ 23 billion, more than the combined income of the National Football League, Major League Baseball and the National Basketball Association. was this a big deal over time.
While these drugs reduced sugar levels, clinically important outcomes, such as reducing heart attacks or strokes, blindness, or other complications of the disease were not improved. All diabetes industry revolved around reducing high blood glucose levels rather than actually help patients. The disease was one of increased insulin resistance, however, it is based treatments in reducing blood sugar in place. We treat the symptoms rather than the actual disease.
Follow the Money
In 2003, the American Diabetes Association changed the definition of prediabetes adding an additional 46 million adults in their ranks. In 2010, the definition was further expanded by the use of hemoglobin A1C. Ostensibly to help with early diagnosis and treatment, it is perhaps no coincidence that 9 out of 14 external experts on this panel worked in various capacities with the giant pharmaceutical companies that made drugs for diabetes and stopped to pick up an endless stream of money.
While individual members were paid millions of dollars, the association itself reaped more than $ 7 million in 2004 pharmacist 'partners'. By 2012, more than 50% of the US population would be considered either diabetic or pre-diabetic. Mission accomplished. Cha Ching. It had been created the market for the drug.
Conflicts of interest get worse. In 2008, a joint statement issued by the American College of Endocrinology and the American Association of Clinical Endocrinologists r eleased a joint statement on the pre-diabetes encourage doctors to consider the drug treatment of patients high risk despite the fact that however drug had been approved by the FDA.
If these impartial academics giving their honest opinions? Barely. 13 of the 17 members of that group were paid as speakers and consultants to drug companies for diabetes.
In 2013, these groups 'defense' recommends the drug treatment of pre-diabetes, even more strongly if lifestyle changes do not work out. Altruistic? Barely. That year, more than $ 8 million in money from big pharmaceutical companies helped shape a positive opinion. 
Thirteen of the 19 doctors on the panel that made the recommendation, including its president, were paid as consultants, speakers or consultants of pharmaceutical companies, surprise, surprise did drugs diabetes. Payments amounted to $ 2.1 billion since 2009. While patients could no longer afford their insulin injections, there were a lot of cash for diabetes associations. fancy dinners? Check. luxury travel? Check. big check? Check.
The story would be completely different if these drugs actually helped patients in a meaningful way. In prediabetes, none of the current drugs are approved for use. The reason why we did not use it because they are useless.
detection of diabetes has already been shown to be largely useless with the current crop of drugs. We all agree that Type 2 diabetes is a disease of high insulin resistance, but the current crop of drugs only treat high blood sugar levels.
DT2, in its essence, is a disease of excess sugar in the body, not just the blood. However, most of our medicines, metformin insulin not release the body of the sugar. Only leads blood and body. But if this sugar is toxic in the blood, why not be toxic in the body?
We are moving only sugar a place where we can see it (the blood) to things somewhere not (the body) and can then pretending to get better, but knowing all the time we have not done one difference. Where changes in lifestyle clearly improves health, medicines as clearly no.
Projection only leads to better results if there is a rational treatment. Since our treatment of prediabetes is ineffective drugs, early diagnosis is useless. But this matters little inconvenient fact that the big pharmaceuticals and their henchmen. While controlled diabetes associations, there was no cash to be made.
This largely explains the resistance of Associations and endocrinologists of diabetes in the world to recognize the devastating truth - that insulin just does not help the long-term patients. With so much money on the table, who do you think all funds research in universities, pays all tuition, sponsors all events "diabetes"? The largest insulin. However, the piper must be paid. The currency depreciation is blindness, organ failure, amputations and death.
The post The Economics of Diabetes - DT2 12 appeared first on https://intensivedietarymanagement.com/diabetes-economy-t2d/
Thanks for Reading The Economics of Diabetes - DT2 12
You are now reading the article The Economics of Diabetes - DT2 12 Url Address https://exerciseplanstoloseweight.blogspot.com/2016/04/the-economics-of-diabetes-dt2-12.html
0 Response to "The Economics of Diabetes - DT2 12"
Posting Komentar